Sahm Adrangi’s Kerrisdale knifes Proteostasis’ 'breakthrough' cystic fibrosis data in a brutal biotech short attack
Sahm Adrangi and his SWAT team at Kerrisdale Capital have put another biotech in their cross hairs.
The high-profile biotech investor — who’s taken on a group of biotechs that range from Bavarian Nordic to Prothena with a series of brutal short attacks — is now ready to call Proteostasis’ $PTI work on cystic fibrosis a bomb in the making.
“We looked at it,” Adrangi tells me, “and decided to take a closer look after it spiked” in the wake of the FDA’s breakthrough drug designation.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
